A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
- 21 January 2009
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 18 (2), 189-197
- https://doi.org/10.1517/13543780802691068
Abstract
Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular...Keywords
This publication has 43 references indexed in Scilit:
- The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell deathBlood, 2008
- An update on the clinical development of drugs to disable tumor vasculatureExpert Opinion on Drug Discovery, 2007
- Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional TherapiesCancer Research, 2006
- Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signalingJCI Insight, 2005
- Phase I Trial of Combretastatin A-4 Phosphate with CarboplatinClinical Cancer Research, 2005
- Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 PhosphateJournal of Clinical Oncology, 2003
- Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic ResultsJournal of Clinical Oncology, 2003
- Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic ImplicationsThe Oncologist, 2000
- Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulinBiochemistry, 1989
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989